Effect of the antidepressant agomelatine on the IL-6 pathway in rats exposed to chronic mild stress: role of Suppressor Of Cytokine Signaling 3 (SOCS3) by A.C. Rossetti et al.
Convegno monotematico SIF 
 
 
The stressed brain: 
psychopathologic implications and pharmacological intervention 
 
March 3rd - 4th, 2016 
 
 
Sala Napoleonica - Università degli Studi di Milano  
Via S. Antonio 10 –Milano 
Corso Vittorio Emanuele, n° 59 - 41121 Modena 
ABSTRACT FORM 
 
TITLE 
 
Effect of the antidepressant agomelatine on the il-6 pathway in rats exposed to 
chronic mild stress: role of Suppressor Of Cytokine Signaling 3 (SOCS3) 
Authors 
 
Rossetti A.C.1, Paladini M.S.1, Bruning C.A.2, Racagni G.1, Papp M.3, Riva M.A.1, 
Molteni R1 
Affiliation 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di 
Milano, Milano, Italia 
2Department of Biochemistry and Molecular Biology, Federal University of Santa 
Maria, Santa Maria, RS, Brazil. 
3Institute of Pharmacology, Polish Academy of Sciences, Kracow, Poland. 
ABSTRACT 
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Major depression (MD) is a debilitating disorder whose treatment is being 
challenged by the high rate of failure and relapse of the pathology. Among the 
molecular systems thought to be involved in the MD etiology and in the mechanism 
of action of antidepressant drugs, inflammation has emerged as an important actor 
(Miller and Raison, 2015). In particular, increased levels of pro-inflammatory 
cytokines have been observed in the plasma and cerebrospinal fluid of depressed 
patients and, among these inflammatory mediators, interleukin (IL-) 6 has been 
recently proposed to play a crucial role (Fonseka et al., 2015). IL-6 triggers a peculiar 
pathway comprising the JAK/STAT signaling proteins and characterized by a specific 
negative feedback loop exerted by the cytoplasmic protein, SOCS3 (Suppressor Of 
Cytokine Signalling-3). 
We have recently demonstrated that a chronic mild stress (CMS) paradigm able to 
induce a depressive-like phenotype, up-regulates the expression of different pro-
inflammatory cytokines in the rat brain and that pharmacological treatment with the 
antidepressant agomelatine was able to normalize not only the pathologic 
phenotype but also the inflammatory state (Rossetti et al., 2015). In this context, the 
aim of the present work was to further investigate the mechanism underpinning the 
anti-inflammatory activity of agomelatine by evaluating the impact of the drug on IL-
6 pathway in the prefrontal cortex of rats exposed to CMS. 
As expected, stress was able to activate the IL-6 cascade, including SOCS3 gene and 
protein expression and JAK1/STAT3 phosphorilation, without any suppressive effect 
of the feedback-loop inhibition. On the contrary, chronic treatment with 
agomelatine was able not only to normalize the stress-induced activation of IL-6 
signaling, but also to modulate SOCS3 translation and transduction under basal 
conditions. Given the potentiality of IL-6 signaling as target of antidepressant 
treatment, we suggest that SOCS3 modulation might be a valuable goal for new drug 
development. 
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